Trial Profile
A efficacy and safety study of a 10‐day Bismuth quadruple therapy (Pylera) regimen in patients who failed previous therapies and were infected with multiresistant H. pylori strains
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Tripotassium dicitrato bismuthate/tetracycline/metronidazole (Primary) ; Esomeprazole
- Indications Helicobacter pylori infections
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2018 New trial record